MEsenchymal StEm Cells for Multiple Sclerosis (MESEMS)
Read time: 1 mins
Last updated:8th May 2013
A double-blind, randomized, cross-over phase I/II study to evaluate the safety and the efficacy of the intravenous administration of autologous Mesenchymal Stem Cells (MSC) to patients with active multiple sclerosis (MS) resistant to currently available therapies.
|Study start date||2013-05-08|